Tissue-implant interface

The tissue-implant interface is the dynamic zone of interaction between a synthetic medical device and living host tissue. It is characterized by the foreign body response (FBR), a complex biological cascade initiated by the immediate adsorption of blood and interstitial proteins onto the implant surface (Anderson et al., 2008, PMID: 18162407). This protein layer triggers the recruitment of inflammatory cells, including neutrophils and macrophages, which may fuse into foreign body giant cells if the material persists (Franz et al., 2011, PMID: 21565401). The ultimate fate of the interface—whether it results in functional integration, such as osseointegration in orthopedic implants, or failure due to chronic inflammation and dense fibrous encapsulation—is determined by the chemical and physical properties of the biomaterial (Ratner, 2011, PMID: 21744054). While the interface itself is not a single molecular target, it serves as a critical site for pharmacological intervention. Therapeutic strategies often involve the local delivery of anti-inflammatory agents, immunosuppressants, or antibiotics to modulate the host response and prevent complications like aseptic loosening or biofilm-associated infections (Gristina, 1987, PMID: 3306918).

Other names

Biomaterial-tissue interfaceImplant-host interfaceBio-interfaceDevice-tissue interface

Pharmacological agents at the tissue-implant interface typically act by modulating the inflammatory cascade, inhibiting fibroblast or smooth muscle cell proliferation, or preventing bacterial colonization through local delivery systems (Franz et al., 2011, PMID: 21565401).